Nutraceutix Partners with Sinphar in First Overseas Venture

REDMOND, Wash.--Nutraceutix Inc. (OTC BB:NUTX) has partnered with Taipei, Taiwan-based Sinphar Pharmaceutical Co. Ltd. to co-develop dietary supplements and pharmaceutical products for countries including Japan, China and Indonesia. According to Nutraceutix, this was the culmination of six months of discussion between the two companies.

Not only does this agreement allow Nutraceutix to extend into foreign markets for the first time, but as part of the Memorandum of Understanding, Sinphar can offer Nutraceutix products and technologies. In particular, Sinphar will co-develop controlled delivery technology (CDT), nutraceutical and probiotic products for Nutraceutix exclusively for the Taiwan market. Sinphar will manufacture these products in its facility in Taiwan, while Sinphar's Canadian subsidiary, CanCap Pharmaceuticals will coordinate research using Nutraceutix' patented technologies. Sinphar also has cGMP (current Good Manufacturing Practices) facilities in Beijing and Thailand.

Randy Schoenfelt, who recently joined Nutraceutix, will direct the marketing involved in this new venture, and Stephen Turner will direct product development.

For more information, visit www.sinphar.com or www.nutraceutix.com.